SlidesetHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #2 In Addition to Their Ability to Induce Resistance to Antiretrovirals, Integrase Inhibitors and Lenacapavir Resistance Mutations Enable HIV-1 to Evade Recognition by the Innate Immune System - Elisa TeyssouView Slideset
SlidesetHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #1 Comparable Dynamics of Cell-Associated HIV-RNA, Total and Intact Proviral HIV-1 DNA in Virologically Suppressed People with HIV Switching to 2DR or Continuing 3DR Over an 18-Month Follow-Up - Lia FiaschiView Slideset
JAJuan AmbrosioniMD, PhDSlidesetHIV23rd European Meeting on HIV & Hepatitis 2025Efficacy, Toxicity and Adherence Considerations - Juan AmbrosioniView Slideset
FCFrancesca Ceccherini-SilbersteinPhDSlidesetHIVViral Hepatitis and Liver DiseaseRSVCOVID-1923rd European Meeting on HIV & Hepatitis 2025How to Improve Fruitful Dialogue between the Virology Lab and Clinicians (Lab Manager Perspective) - Francesca Ceccherini SilbersteinView Slideset
JDJohn DitekemenaMD, MPH, PhDSlidesetTuberculosis2nd Conference on Innovations in Tuberculosis 2025Towards Integrated Prevention, Treatment, and Service Provision for TB, HIV and NCDs - John DitekemenaView Slideset
BdJBouke de JongMSc, PhDSlidesetTuberculosis2nd Conference on Innovations in Tuberculosis 2025Should Africa Move to Whole Genome Sequencing for Drug Resistance Testing? Con Standpoint - Bouke de Jong View Slideset
SlidesetTuberculosis2nd Conference on Innovations in Tuberculosis 2025Abstract #17 - Economic Recovery Among Patients Following Drug-Susceptible Tuberculosis Treatment in Johannesburg, South Africa - Kamban HirasenView Slideset
SlidesetTuberculosis2nd Conference on Innovations in Tuberculosis 2025Abstract #49 - Managing TB/HIV Comorbidities Among Children and Adolescents Co-Infected With TB & HIV Through Targeted Structural Interventions in Northern Nigeria: A Pathway to Improved Health Outcomes - Charles OdimaView Slideset
Slideset2nd Conference on Innovations in Tuberculosis 2025Abstract #34 - Comparative Pharmacokinetics of Dolutegravir in Children With HIV With and Without TB Co-Infection - Charles Martyn-DickensView Slideset
SlidesetTuberculosis2nd Conference on Innovations in Tuberculosis 2025Abstract #11 - The Continued Rise of Bedaquiline-Resistant Tuberculosis in Mozambique - Cláudio AbujateView Slideset
SlidesetTuberculosis2nd Conference on Innovations in Tuberculosis 2025Abstract #12 - Impact of Mycobacterium tuberculosis Strains With rpoB I491F Mutation on Uptake and Outcomes of BPaLM Regimen in Eswatini - Debrah VambeView Slideset
SlidesetTuberculosis2nd Conference on Innovations in Tuberculosis 2025Abstract #25 - Evaluating Targeted Next-Generation Sequencing for Diagnosing Drug- Resistant Tuberculosis in Namibia - Lusia MhuuluView Slideset
